Therapy with plasma purified alpha1-antitrypsin (Prolastin®) induces time-dependent changes in plasma levels of MMP-9 and MPO.
The common Z mutation (Glu342Lys) of α1-antitrypsin (A1AT) results in the polymerization and intracellular retention of A1AT protein. The concomitant deficiency of functional A1AT predisposes PiZZ subjects to early onset emphysema. Clinical studies have implied that, among the biomarkers associated...
Main Authors: | Janine Koepke, Marc Dresel, Severin Schmid, Timm Greulich, Björn Beutel, Bernd Schmeck, Claus Franz Vogelmeier, Sabina Janciauskiene, Andreas Rembert Koczulla |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2015-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4311911?pdf=render |
Similar Items
-
The effects of weekly augmentation therapy in patients with PiZZ α1-antitrypsin deficiency
by: Schmid ST, et al.
Published: (2012-09-01) -
Alpha-1-antitrypsin deficiency: increasing awareness and improving diagnosis
by: Timm Greulich, et al.
Published: (2016-02-01) -
How Can We Improve the Detection of Alpha1-Antitrypsin Deficiency?
by: Ilaria Ferrarotti, et al.
Published: (2015-01-01) -
The Distribution of Alpha-1 Antitrypsin Genotypes Between Patients with COPD/Emphysema, Asthma and Bronchiectasis
by: Veith M, et al.
Published: (2020-11-01) -
The Multifaceted Effects of Alpha1-Antitrypsin on Neutrophil Functions
by: Sabina Janciauskiene, et al.
Published: (2018-04-01)